Secondary surgical cytoreduction for advanced epithelial ovarian cancer: Patient selection and review of the literature

Cancer

Volumn 78, Issue 10, 1996, Pages 2049-2062

  Bristow, Robert E ^a   Lagasse, Leo D ^a,b   Karlan, Beth Y ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

interval cytoreduction; recurrent ovarian cancer; second look laparotomy; secondary surgical cytoreduction

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; FEMALE; HUMAN; LAPAROTOMY; MEDICAL LITERATURE; OVARY CANCER; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL RATE;

FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; REOPERATION;

EID: 0029910164     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961115)78:10<2049::AID-CNCR4>3.0.CO;2-J     Document Type: Article

References (57)

1. Ozols RF, Rubin SC, Dembo AJ, Robboy SJ. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practice of gynecologic oncology. Philadelphia: J. B. Lippincott, 1992:731-81.
2. Meigs JV. Tumors of the female pelvic organs. New York, NY: McMillan, 1935.
3. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Monogr Natl Cancer Inst 1975;42:101-4.
4. Hacker NF, Berek JS, LaGasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-20.
5. Hoskins WJ, Rubin SC. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 1991;18:213-21.
6. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer:a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-66.
7. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Herman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-80.
8. Silberman AW. Surgical debulking of tumors. Surg Gynecol Obstet 1982;155:577-85.
9. Sugarbaker PH. Cytoreductive surgery and intraperitoneal chemotherapy with peritoneal spread of cystadenocarcinoma. Eur J Surg Suppl 1991;561:75-82.
10. Skipper HE. Adjuvant chemotherapy. Cancer 1978;41:936-40.
11. Griswold DP, Schabel FM, Wilcox WS, Simpson-Herren L, Skipper HE. Success and failure in the treatment of solid tumors. I. Effects of cyclophosphamide (NSC-26271) on primary and metastatic plasmacytoma in the hamster. Cancer Chem Rep 1968;52:345-87.
12. Goldie JH, Goldman JA. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-33.
13. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61:1307-17.
14. Delcos L, Quinlan EJ. Malignant tumors of the ovary managed with postoperative megavoltage irradiation. Radiology 1969;93:659-63.
15. Ehrlich CE, Einhorn L, Williams SD, Morgan J. Chemotherapy for stage III-1V epithelial ovarian cancer with cis-dichlorodiammineplatinum II, adriamycin, and cyclophosphamide:a preliminary report. Cancer Treat Rep 1979;63:281-8.
16. Greco FA, Julian CG, Richardson RL, Burnett L, Hande KR, Oldham RK. Advanced ovarian cancer:brief intensive combination chemotherapy and second-look operation. Obstet Gynecol 1981;58:199-205.
17. Young RC, Chabner BA, Hubbard SP, Fisher RJ, Bender RA, Anderson T, et al. Advanced ovarian adenocarcinoma:a prospective clinical trial of melphelan (L-PAM) versus combination chemotherapy. N Engl J Med 1978;229:1261-6.
18. Williams L. The role of secondary cytoreductive surgery in epithelial ovarian malignancies. Oncology 1992;6:25-32.
19. Burke TW, Morris M. Secondary cytoreductive operations. In: Rubin SC, Sutton GP, editors. Ovarian cancer. New York, NY: McGraw-Hill, 1993:301-12.
20. Burke TW, Morris M. Secondary cytoreductive surgery for ovarian cancer. Obstet Gynecol Clin North Am 1994;21:167-78.
21. Janicke F, Holscher M, Kuhn W, von Hugo R, Pache L, Siewert JR, et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992;70:2129-36.
22. Vaccarello L, Rubin SC, Vlamis V, Wong G, Jones WB, Lewis JL, et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 1995;57:61-5.
23. Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 1993;11:434-9.
24. Morris M, Gershenson DM, Wharton JT, Copeland LJ, Edwards CL, Stringer CA. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 1989; 34:334-8.
25. Eisenkop SM, Friedman RL, Wang H. Secondary cytoreductive for recurrent ovarian cancer. A prospective study. Cancer 1995;76:1606-14.
26. Berek JS, Hacker NF, LaGasse LD, Nieberg RK, Elashoff RM. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 1983;61:189-93.
27. Ovarian cancer screening, treatment, and followup. NIH Consensus Statement. 1994;12(3):1-24.
28. Lippman SM, Alberts DS, Slymen DJ, Weiner S, Aristizabal SA, Luditch A, et al. Second-look laparotomy in epithelial ovarian cancer. Cancer 1988;61:2571-7.
29. Bertelson K. Tumor reduction surgery and long-term survival in advanced ovarian cancer:a DACOVA study. Gynecol Oncol 1990;38:203-9.
30. Podczaski E, Manetta A, Kaminski P, Ricelli A, Larson J, De-Geest K, et al. Survival of patients with ovarian epithelial carcinomas after second-look laparotomy. Gynecol Oncol 1990;36:43-7.
31. Podratz KC, Schray MF, Wieand HS, Edmonson JH, Jeffries JH, Long HI, et al. Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol 1988;31:9-21.
32. Heintz APM, Van Oosterom AT, Trimbos JBMC, Schaberg A, Van der Velde E, Nooy M. The treatment of advanced ovarian carcinoma (II):interval reassessment operations during chemotherapy. Gynecol Oncol 1988;30:359-71.
33. Hoskins WJ, Rubin SC, Dulaney E, Chapman D, Almadrones L, Saigo P, et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 1989; 34:365-71.
34. Potter ME, Hatch KD, Soong SJ, Partridge EE, Austin IM, Shingleton HM. Second-look laparotomy and salvage therapy:a research modality only? Gynecol Oncol 1992;44:3-9.
35. Morgan MA, Rubin SC. Secondary cytoreduction in epithelial ovarian cancer. Crit Rev Oncol Hematol 1995;18:1-8.
36. Podratz KC. Response to discussion:evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol 1988;31:24.
37. Chambers SK, Chambers JT, Kohorn EI, Lawrence R, Schwartz PE. Evaluation of the role of second-look surgery in ovarian cancer. Obstet Gynecol 1988;72:404-8.
38. Luesley D, Lawton F, Blackledge G, Hilton C, Kelly K, Rollason T, et al. Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet 1988;2:599-603.
39. Hainsworth JD, Grosh WW, Burnett LS, Jones HW, Wolff SN, Greco FA. Advanced ovarian cancer:long-term results of treatment with intensive cisplatin-based c chemotherapy of brief duration. Ann Intern Med 1988;108:165-70.
40. Miller DS, Spirtos NM, Ballon SC, Cox RS, Soriero OM, Teng NNH. Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Cancer 1992; 69:502-10.
41. Hoskins WJ. The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer. Baillieres Clin Obstet Gynaecol 1989;3:59-71.
42. Ng LW, Rubin SC, Hoskins WJ, Jones WB, Hakes TB, Markman M, et al. Aggressive chemosurgical debulking in patients with advanced ovarian cancer. Gynecol Oncol 1990;38:358-63.
43. Vogl SE, Seltzer V, Calanog A, Moukhtar M, Camach F, Kaplan B, et al. "Second effort" surgical resection for bulky ovarian cancer. Cancer 1984;54:2220-5.
44. Neijt JP, Aartsen EJ, Bouma J, Heintz APM, van Lent M, van Lindert ACM. Cytoreductive surgery with or without preceeding chemotherapy in ovarian cancer. Prog Clin Biol Res 1985;201:217-33.
45. Lawton FG, Redman CWE, Luesley DM, Chan KK, Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol 1989; 73: 61-5.
46. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991;42:146-50.
47. Wils J, Blijham G, Naus A, Beider C, Boschma F, Bron H, et al. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 1986;4:1068-73.
48. Wiltshaw E, Raju KS, Dawson I. The role of cytoreductive surgery in advanced carcinoma of the ovary:an analysis of primary and secondary surgery. Br J Obstet Gynaecol 1985;92:522-7.
49. Redman CWE, Warwick J, Luesley DM, Varma R, Lawton FG, Blackledge GRP. Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 1994;101:142-6.
50. van der Burg MEL, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629-34.
51. Smith JP, Rutledge F. Chemotherapy in the treatment of cancer of the ovary. Am J Obstet Gynecol 1970; 107:691-703.
52. Lawton FG. Secondary debulking in ovarian cancer:is it all in the timing? Curr Opin Obstet Gynecol 1995;7:1-3.
53. Lawton FG, Kelly KA, Sant Cassis L, Blackledge G. Speed of response to platinum-based chemotherapy:implications for the management of epithelial ovarian cancer. Eur J Cancer Clin Oncol 1987;23:1071-5.
54. Morris M, Gershenson DM, Wharton JT. Secondary cytoreductive surgery in epithelial ovarian cancer:nonresponders to first-line therapy. Gynecol Oncol 1989;33:1-5.
55. Michel G, Zarca D, Castaigne D, Prade M. Secondary cytoreductive surgery in ovarian cancer. Eur J Surg Oncol 1989;15:201-4.
56. Rubin SC, Lewis JL. Second-look surgery in ovarian carcinoma. Crit Rev Oncol Hematol 1988;8:75-91.
57. Blythe JG, Wahl TP. Debulking surgery:does it increase the quality of survival? Gynecol Oncol 1982;14:396-408.